IVERIC bio

IVERIC bio Net Debt/FCF

Delisted

The Net Debt to Free Cash Flow Ratio of IVERIC bio (ISEE) as of Oct 22, 2026 is 3.34. In the previous year, Net Debt to Free Cash Flow Ratio was 3.86 — a change of -13.32% (lower).

Net Debt/FCF

3.34

YoY

-13.32%

Last updated:

Net Debt to Free Cash Flow Ratio of IVERIC bio is 2022 3.34 . Net Debt to Free Cash Flow Ratio of IVERIC bio was 2021 3.86 . It decreases by -13.32% lower compared to the previous year.

The IVERIC bio Net Debt/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/FCF
Date
Net Debt/FCF
Jan 1, 2015
3.66 USD
Jan 1, 2016
2.65 USD
Jan 1, 2017
1.37 USD
Jan 1, 2018
3.10 USD
Jan 1, 2019
2.57 USD
Jan 1, 2020
3.16 USD
Jan 1, 2021
3.86 USD
Jan 1, 2022
3.34 USD
The IVERIC bio Net Debt/FCF history
YEARNet Debt/FCFYoY
3.34-13.32%
3.86+22.10%
3.16+22.83%
2.57-17.10%
3.10+126.45%
1.37-48.27%
2.65-27.50%
3.66-186.28%
-4.24—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IVERIC bio Stock analysis

What does IVERIC bio do? Iveric Bio Inc is a leading biopharmaceutical company specializing in the discovery and development of therapy options for eye diseases. The company was originally founded in 1989 as Ophthotech Corp. and is headquartered in New York City. Iveric Bio Inc aims to develop innovative treatments for eye diseases that can improve the lives of millions of people. The eye diseases that Iveric Bio Inc is fighting range from retinal diseases to degenerative eye diseases. Iveric Bio Inc has a strong business model, focusing on innovation to develop new treatment methods. The company invests in research and development to create a solid pipeline of new therapies, while also closely collaborating with the medical community to ensure that the therapies meet the needs of patients and doctors. Iveric Bio Inc's therapy options are focused on treating eye diseases such as age-related macular degeneration, diabetic retinopathy, and other retinal diseases. Iveric Bio Inc also focuses on preserving vision and improving the quality of life for people with glaucoma and other eye diseases. Iveric Bio Inc's portfolio currently includes two main products: Zimura and GATHER1. Zimura is a potentially groundbreaking medication developed for the treatment of dry age-related macular degeneration (AMD). It is currently being studied in late-stage clinical trials and could play an important role in the future of AMD treatment. GATHER1, the other main product of Iveric Bio Inc, is a clinical drug candidate developed for the treatment of geographic atrophy (GA). GA is an advanced form of dry AMD associated with the destruction of cells in the retina and a loss of vision. GATHER1 has been deemed promising in Phase II trials and is currently being tested in Phase III trials. Overall, Iveric Bio Inc has an excellent track record in the development of therapy options for eye diseases. The company has a wide range of treatment possibilities in the pipeline aimed at meeting the need for effective therapies for various eye diseases. Additionally, Iveric Bio Inc works closely with the medical community and other biopharmaceutical companies to share the latest research findings and advance the treatment of eye diseases. Overall, Iveric Bio Inc is an emerging biopharmaceutical company with a strong focus on research and development. The company has a strong business model and a robust pipeline of therapy options aimed at improving eye health and the quality of life for millions of people. IVERIC bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IVERIC bio stock

Net Debt to Free Cash Flow Ratio of IVERIC bio is 3.34 in 2022.

Net Debt to Free Cash Flow Ratio of IVERIC bio changed from 3.86 to 3.34, representing a -13.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Free Cash Flow Ratio IVERIC bio since 2006 – with annual values, charts, and detailed analysis.

Net Debt/FCF indicates how many years it would take to repay net debt using free cash flow. Lower ratios suggest faster deleveraging potential.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Free Cash Flow Ratio's IVERIC bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — IVERIC bio

All Key Metrics — IVERIC bio